SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated announced today that the Company will present at BIOCOM’s First Annual San Diego Investor Conference on November 15 at approximately 4:20 p.m. Pacific Time. The presentation is scheduled to be webcast live and may be accessed through a link on the investment information section of Gen-Probe’s website at www.gen-probe.com. The webcast will be available for 30 days following the event.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 20 years of NAT expertise, and received the 2004 National Medal of Technology, America’s highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 900 people. For more information, go to www.gen-probe.com.
About BIOCOM
BIOCOM is a premier life science industry association representing nearly 500 member companies. The association focuses on initiatives that positively influence the growth of the life science industry, including capital formation, public policy, workforce development, and scientific discovery and development. For more information on BIOCOM or the San Diego regional life sciences community, please visit the organization’s Web site at www.biocom.org.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the quarter ended September 30, 2006, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Contact: Paula Izidoro Investor Relations 858-410-8904
Gen-Probe Incorporated
CONTACT: Paula Izidoro, Investor Relations of Gen-Probe Incorporated,+1-858-410-8904
